Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M. Sinner F, et al. Among authors: de toni en. Cancers (Basel). 2022 Dec 2;14(23):5966. doi: 10.3390/cancers14235966. Cancers (Basel). 2022. PMID: 36497447 Free PMC article.
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.
Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Spahn S, et al. Among authors: de toni en. Cancers (Basel). 2020 Dec 18;12(12):3830. doi: 10.3390/cancers12123830. Cancers (Basel). 2020. PMID: 33353145 Free PMC article.
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M. Öcal O, et al. Among authors: de toni en. J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485. doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14. J Cancer Res Clin Oncol. 2022. PMID: 33855585 Free PMC article. Clinical Trial.
Current State of Multidisciplinary Treatment in Cholangiocarcinoma.
Ben Khaled N, Jacob S, Rössler D, Bösch F, De Toni EN, Werner J, Ricke J, Mayerle J, Seidensticker M, Schulz C, Fabritius MP. Ben Khaled N, et al. Among authors: de toni en. Dig Dis. 2022;40(5):581-595. doi: 10.1159/000520346. Epub 2021 Oct 25. Dig Dis. 2022. PMID: 34695826 Free article. Review.
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN. Ben Khaled N, et al. Among authors: de toni en. Future Oncol. 2022 Apr;18(12):1423-1435. doi: 10.2217/fon-2021-1261. Epub 2022 Jan 27. Future Oncol. 2022. PMID: 35081747
Reply.
Ben Khaled N, Rössler D, Reiter FP, Mayerle J, Lange CM, Seidensticker M, Guba M, De Toni EN. Ben Khaled N, et al. Among authors: de toni en. Liver Transpl. 2022 May;28(5):897-898. doi: 10.1002/lt.26410. Epub 2022 Mar 10. Liver Transpl. 2022. PMID: 35090084 No abstract available.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D, Öcal O, Philipp AB, Markwardt D, Munker S, Mayerle J, Jochheim LS, Hammer K, Lange CM, Geier A, Seidensticker M, Reiter FP, De Toni EN, Ben Khaled N. Roessler D, et al. Among authors: de toni en. J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864269 Free PMC article.
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN. Ben Khaled N, et al. Among authors: de toni en. Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240. Cancers (Basel). 2022. PMID: 36358659 Free PMC article.
112 results